

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION BY APPLICANT</b>  (Use several sheets if necessary)	DOCKET NUMBER Z70538-1P US	US APPLICATION NUMBER Not Known 10/009,574
	APPLICANT AstraZeneca AB Reinstein et al.	
	FILING DATE 4-22-02	GROUP ART UNIT Not Known 1624

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Public Date	Country	Class	Subclass	Translation	
						Yes	No
BC	WO 97/32037	4 Sept 1997	PCT WIPO	—	—		
BC	WO 98/04289	5 Feb 1998	PCT WIPO	—	—		
BC	EP 0 830 864 A1	25 March 1998	Europe	—	—		
BC	WO 00/54764	21 Sept 2000	PCT WIPO	—	—		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	PCT/GB00/01875 International Search Report
BC	S. J. Nasr. NASR Psychiatric Services PC, Michigan City, USA; XP-001009548 <i>Resolution of Rapid Weight Gain on Olanzapine after substitution with Quetiapine, 2000.</i>
BC	J. B. Robertson jr., L Treosti, K.D. Walker, Center for Family Psychiatry, Tennessee, USA; XP001010838 <i>Successful use of high dos quetiapine in a patient with a psychiatric disorder resistant to olanzapine, 2000.</i>
BC	Lalith K. Misra, DVM, PhD, DO, et al; University of South Dakota School of Medicine; XP-000901163 <i>Quetiapine: A New Atypical Antipsychotic</i> ; June, 1998; pp 189 - 193
BC	Michael J. Reinstein, et al; Clinical Research Dept, Forest Foundation Inc., Chicago, Illinois, USA; XP001009552 <i>Effect of Clozapine-Quetiapine Combination Therapy on Weight and Glycaemic Control Preliminary Findings</i> ; Clin Drug Invest 1999 Aug; 18(2); pp 99 - 104
BC	Herbert Y. Meltzer, M.D. et al.; XP-001009550 <i>Adverse Effects of the Atypical Antipsychotics</i> (Collaborative Working Group on Clinical Trial Evaluations); J. Clin. Psychiatry 1998;59[suppl 12]: pp17-22
BC	Josee E. Leysen et al; XP-001009585 <i>Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects</i> ; International Journal of Psychiatry in Clinical Practice 1998 Volume 2; pp S3 - S17

EXAMINER Brenda Coleman	DATE CONSIDERED June 10, 2004
----------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.